Brigatinib Products | Cleanchem - Brigatinib is a tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer (NSCLC) with ALK mutations. It works by inhibiting the activity of the ALK protein, which is involved in cancer cell growth. It is typically used when other therapies, such as crizotinib, fail.

Brigatinib

Cat. No: CL-BGT-001

CAS No: 1197953-54-0

Mol. F: C29H39ClN7O2P

Mol. Wt: 584.1

Inv. Status: Custom Synthesis

5-Methyl Brigatinib

Cat. No: CL-BGT-002

CAS No: 1197961-02-6

Mol. F: C30H41ClN7O2P

Mol. Wt: 598.1

Inv. Status: Custom Synthesis

Demethyl Brigatinib

Cat. No: CL-BGT-003

CAS No: 1197958-75-0

Mol. F: C28H37ClN7O2P

Mol. Wt: 570.1

Inv. Status: Custom Synthesis

O-Ethyl Brigatinib

Cat. No: CL-BGT-004

CAS No: 1197960-18-1

Mol. F: C30H41ClN7O2P

Mol. Wt: 598.1

Inv. Status: Custom Synthesis

Brigatinib Impurity 1

Cat. No: CL-BGT-005

CAS No: NA

Mol. F: C38H55ClN10O2

Mol. Wt: 719.4

Inv. Status: Custom Synthesis

Brigatinib Impurity 2

Cat. No: CL-BGT-006

CAS No: 1197959-30-0

Mol. F: C24H29ClN5O3P

Mol. Wt: 502

Inv. Status: Custom Synthesis

Brigatinib Impurity 3

Cat. No: CL-BGT-007

CAS No: 1259274-28-6

Mol. F: C21H28Cl2N6O

Mol. Wt: 451.4

Inv. Status: Custom Synthesis

Brigatinib D3

Cat. No: CL-BGT-008

CAS No: 2055306-71-1

Mol. F: C29H36D3ClN7O2P

Mol. Wt: 587.1

Inv. Status: Custom Synthesis

Brigatinib D8

Cat. No: CL-BGT-009

CAS No: 2055306-74-4

Mol. F: C29H31D8ClN7O2P

Mol. Wt: 592.2

Inv. Status: Custom Synthesis

Brigatinib D11

Cat. No: CL-BGT-010

CAS No: 2055306-76-6

Mol. F: C29H28D11ClN7O2P

Mol. Wt: 595.2

Inv. Status: Custom Synthesis